Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Stevenson

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Maturitas|September 24, 2024
Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic populationJohn C Stevenson, Mulan Ren, Elke Kahler, et al.
Climacteric : the Journal of the International Menopause Society|July 30, 2024
Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and ChinaQi Yu, John C Stevenson, Tetiana Tatarchuk, et al.
Maturitas|April 8, 2020
Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysisPanagiotis Anagnostis, Patroklos Theocharis, Konstantinos Lallas, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 8, 2024
Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysisTetiana Tatarchuk, John C Stevenson, Qi Yu, et al.
Climacteric : the Journal of the International Menopause Society|October 30, 2024
Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass indexMulan Ren, Qi Yu, Marcelo Graziano Custodio, et al.
Climacteric : the Journal of the International Menopause Society|August 7, 2025
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USAJohn C Stevenson, Rodney Baber, Risa Kagan, et al.
Maturitas|April 9, 2017
Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition StatementFaustino R Pérez-López, Iuliana Ceausu, Herman Depypere, et al.
Maturitas|May 11, 2005
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapySven O Skouby, Farook Al-Azzawi, David Barlow, et al.
Maturitas|September 14, 2016
A model of care for healthy menopause and ageing: EMAS position statementPetra Stute, Iuliana Ceausu, Herman Depypere, et al.
Maturitas|November 25, 2017
Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guideAntonio Cano, Peter Chedraui, Dimitrios G Goulis, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Maturitas|September 24, 2024
Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic populationJohn C Stevenson, Mulan Ren, Elke Kahler, et al.
Climacteric : the Journal of the International Menopause Society|July 30, 2024
Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and ChinaQi Yu, John C Stevenson, Tetiana Tatarchuk, et al.
Maturitas|April 8, 2020
Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysisPanagiotis Anagnostis, Patroklos Theocharis, Konstantinos Lallas, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 8, 2024
Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysisTetiana Tatarchuk, John C Stevenson, Qi Yu, et al.
Climacteric : the Journal of the International Menopause Society|October 30, 2024
Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass indexMulan Ren, Qi Yu, Marcelo Graziano Custodio, et al.
Climacteric : the Journal of the International Menopause Society|August 7, 2025
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USAJohn C Stevenson, Rodney Baber, Risa Kagan, et al.
Maturitas|April 9, 2017
Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition StatementFaustino R Pérez-López, Iuliana Ceausu, Herman Depypere, et al.
Maturitas|May 11, 2005
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapySven O Skouby, Farook Al-Azzawi, David Barlow, et al.
Maturitas|September 14, 2016
A model of care for healthy menopause and ageing: EMAS position statementPetra Stute, Iuliana Ceausu, Herman Depypere, et al.
Maturitas|November 25, 2017
Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guideAntonio Cano, Peter Chedraui, Dimitrios G Goulis, et al.
Pageof 10